Clinuvel completes ZEROKIN self-injection device
Clinuvel Pharmaceuticals unveils its proprietary ZEROKIN single-use injection device and outlines a Class II FDA 510(k) and EU CE-mark regulatory path.
Rhea-AI Filing Summary
Clinuvel Pharmaceuticals Ltd (CUVL) reported that it has completed development of ZEROKIN™, a proprietary single-use subcutaneous administration device intended for controlled-release formulations, initially focused on melanocortin peptides developed at its Singapore R&D center VALLAURIX.
The company has submitted an intellectual property application for ZEROKIN™, plans to appoint a commercial manufacturer, and intends to pursue a Class II medical device regulatory pathway, including U.S. FDA clearance via the 510(k) process and an application for CE marking under EU Medical Device Regulations. ZEROKIN™ is designed for both hospital use and self-administration, aligning with growth in the global market for self-administered injection devices.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
controlled-release formulations medical
Class II device regulatory
FDA 510(k) regulatory
CE marking regulatory
EU Medical Device Regulations regulatory
melanocortins medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Clinuvel Pharmaceuticals (CUVL) announce about the ZEROKIN device?
What is the intended regulatory pathway for Clinuvel’s ZEROKIN device?
How does ZEROKIN support Clinuvel Pharmaceuticals (CUVL) peptide programs?
What market context did Clinuvel provide for injection and self-administered devices?
Is ZEROKIN already approved for human use according to Clinuvel’s 6-K?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number: 001-43353
CLINUVEL PHARMACEUTICALS LIMITED
Level 22, 535 Bourke Street
Melbourne, VIC 3000
Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On September 8, 2026, Clinuvel Pharmaceuticals Limited filed with the Australian Securities Exchange an announcement captioned “CLINUVEL develops proprietary ZEROKIN™ device”, a copy of which announcement is attached to this Form 6-K as Exhibit 99.1.
Exhibits
| Exhibit No. | Description | |
| 99.1 | Press release dated September 8, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CLINUVEL PHARMACEUTICALS LIMITED | ||
| Date: September 8, 2026 | By: | /s/ Philippe Wolgen |
| Name: | Philippe Wolgen | |
| Title: | Managing Director and Chief Executive Officer | |
Exhibit 99.1
CLINUVEL develops proprietary ZEROKIN™ device
Single-use administration device for controlled-release formulations
Executive Summary
| ● | ZEROKIN™ novel single-use administration device for controlled-release formulations | |
| ● | IP application submitted | |
| ● | commercial manufacturer to be appointed | |
| ● | dossier for Class II to be submitted as FDA 510(k) |
Figure 1. Illustration of single-use administration device ZEROKIN™
Melbourne / Singapore – 08 September 2026 – CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced that it has completed the development of ZEROKIN™, a proprietary single-use administration device for subcutaneous drug delivery. ZEROKINTM will be used to administer novel controlled-release formulations developed out of CLINUVEL’s Research, Development and Innovation Center in Singapore (VALLAURIX).
Disposable injectable device
Currently, few commercially available devices are registered for the administration of subcutaneous or intradermal formulations. In developing ZEROKINTM, CLINUVEL sought to engineer a disposable administration device which would be suitable for various formulations. The device is aimed at both hospital use and self-administration, depending on the medication.
VALLAURIX is developing a range of formulatory approaches which lend themselves to the controlled-release delivery of peptides, focused initially on melanocortins, the family of peptides which includes afamelanotide.
US$27.1b global market for injection devices
The global market for self-administered devices is projected to grow from US$27.1 billion in 2026 to US$40.5 billion by 2030. North America dominates the market, accounting for a revenue share of 42.4% in 2024. Demand for self-administration has been driven by a rise in the prevalence of chronic conditions and availability of new classes of therapeutics and peptides which are projected to reach a market value of $133.2 billion by 2030.
Regulatory pathway
ZEROKINTM is intended as a Class II device, which will require registration for human use with the U.S. Food and Drug Administration (FDA) via the 510(k) pathway, and an application for CE marking under the EU Medical Device Regulations.
Commentary
“In parallel to our clinical development programs, our scientific teams have taken extensive feedback on the use of our drug SCENESSE® and other peptides in the clinic to try and anticipate how these products could better serve patient and physician needs,” said Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer. “The bespoke ZEROKINTM device is the direct result of this process, which we will now fast track to finished manufacture and regulatory filing. It is an important step forward alongside our formulation work in Singapore.”
– END –
| ASX Announcement | PAGE 1 OF 2 |
About CLINUVEL PHARMACEUTICALS LIMITED
CLINUVEL is a global biopharmaceutical company focused on developing and delivering innovative therapies for patients with genetic, metabolic, and dermatological disorders. The Company’s portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. CLINUVEL is listed on the Australian Securities Exchange (ASX: CUV) and the Nasdaq Stock Market (Nasdaq: CUVL).
CLINUVEL’s lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Canada, Israel, and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). For further information, visit www.clinuvel.com.
Authorised for ASX release by the Managing Director on behalf of Board of Directors of CLINUVEL PHARMACEUTICALS LTD.
Head of Investor Relations
Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD
Investor Enquiries
https://www.clinuvel.com/investors/contact-us
Forward-Looking Statements
This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “foresee,” “intend,” “likely,” “may,” “objective,” “potential,” “plan,” “predict,” “project,” “seek,” “should,” “will” and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include but are not limited to risks relating to: our ability to develop and commercialise pharmaceutical products; pandemics, epidemics, public health emergencies, geopolitical conflicts, trade restrictions, natural disasters and other disruptions affecting global supply chains, including our ability to develop, manufacture, market and sell biopharmaceutical and PhotoCosmetic products; competition for our products, especially SCENESSE® (afamelanotide 16mg), CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed and characterised by us as PhotoCosmetics; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, the UK, Israel, China, Japan, and/or LATAM regions of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed as PhotoCosmetics which may lead to the Company being unable to launch, supply or serve its commercial markets, special access programs and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare, Medicaid, and U.S. Department of Veteran’s Affairs) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology, cosmetic and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry, cosmetic industry and related industries; potential changes to tax liabilities or legislation; environmental risks including the risk factors described in the Company’s Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission, together with the Company’s announcements lodged with the Australian Securities Exchange. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation except as required by applicable law, the rules of the Australian Securities Exchange, the U.S. Securities and Exchange Commission, Nasdaq, or other applicable regulatory requirements, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.
Contact:
Tel: +61 3 9660 4900
Fax: +61 3 9660 4909
Email: mail@clinuvel.com
Australia (Head Office), Level 22, 535 Bourke Street, Melbourne, Victoria, 3000, Australia
| ASX Announcement | PAGE 2 OF 2 |